Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2

Figure 1 Involvement of annexin A2 in tumor necrosis factor-α ectodomain shedding and release. Quoted and adapted from Ford et al[14]. A: Quantitative analysis of TNF-α shedding during TPA stimulation of HCT116 cells overexpressing AP-tagged proTNF-α and inhibitory effects of ANX A2 siRNA on TNF-α shedding. ^aP < 0.05 vs control for the stimulatory effect, and ^cP < 0.05 vs control for the inhibitory effect; B: Inhibitory effect of ANX A2 siRNA on IL-1β-induced TNF-α release from HCT116 cells. The concentration of TNF-α released into the conditioned medium was measured using ELISA. ^aP < 0.05 vs control for the stimulatory effect, and ^cP < 0.05 vs control for the inhibitory effect; C: Inhibitory effects of ANX A2 siRNA on TPA-induced TNF-α release in U937 cells. The concentration of TNF-α released into the conditioned media was measured using ELISA. ^aP < 0.05 vs control for the stimulatory effect, and ^cP < 0.05 vs control for the inhibitory effect. TNF: Tumor necrosis factor; ANX: Annexin; IL: Interleukin.